Melanoma growth varies enormously from person to person and from one subtype to another, but research on primary skin melanomas puts the median tumor doubling time at roughly three months. Some melanomas spend years as a flat, barely changing patch before becoming dangerous, while others thicken measurably in weeks. The spread between the slowest and fastest cases is so wide that a single number can be misleading, and the factors that push a melanoma toward the fast end of that range are worth understanding.
Tumor Doubling Time in Numbers
Doubling time is the period a tumor needs to double its volume. For primary cutaneous melanoma, one study of cases where diagnosis had been delayed found a median doubling time of 94 days and a mean of 144 days, with individual tumors ranging from about 50 days to over a year.1PubMed. Tumor doubling time of cutaneous melanoma and its metastasis A separate analysis that estimated doubling times from progression-free survival data across multiple cancer types calculated melanoma’s mean doubling time at roughly 3.8 months.2PubMed Central. Estimation of Solid Tumor Doubling Times from Progression-Free Survival Plots Using a Novel Statistical Approach Those two figures sit in the same ballpark, but the range within each dataset is enormous. A melanoma at the slow end might take the better part of a year to double, while one at the fast end doubles in under two months.
Once melanoma has metastasized, the clock speeds up considerably. In the same delayed-diagnosis study, metastatic deposits had a median doubling time of about 33 days and a mean of 64 days, significantly faster than the primary tumors they came from.1PubMed. Tumor doubling time of cutaneous melanoma and its metastasis This acceleration matters for understanding why early detection is so heavily emphasized: a tumor that takes three months to double while still in the skin may double in a month or less once it has seeded elsewhere in the body.
Superficial Spreading Versus Nodular Melanoma
The two most common histological subtypes of cutaneous melanoma behave quite differently. Superficial spreading melanoma, which accounts for the majority of cases, tends to grow outward across the skin surface before it begins to invade downward. This horizontal phase can last months to years, during which the lesion may look like an irregularly pigmented, gradually expanding flat spot. Nodular melanoma, by contrast, appears to skip much of that horizontal phase and grows vertically into deeper skin layers from relatively early on.
For a long time, dermatology textbooks presented these two as stages of the same process, with nodular melanoma simply being superficial spreading melanoma that had “progressed.” Research has challenged that model. Clinical, pathological, and molecular data indicate that superficial spreading and nodular melanomas may evolve as distinct biological entities rather than points along a single timeline.3Europe PMC. Superficial spreading and nodular melanoma are distinct biological entities: a challenge to the linear progression model The practical takeaway is that nodular melanoma does not necessarily “start slow and speed up.” It can be dangerous from the start, often presenting as a raised, dome-shaped bump that thickens rapidly over a matter of weeks. Waiting for a flat lesion to slowly evolve before becoming concerned can mean missing this subtype entirely.
Who Gets Fast-Growing Melanomas
Not everyone faces the same risk of a rapidly advancing tumor. Research has identified several patient and tumor characteristics linked to faster growth. In a study examining growth rates across a large melanoma population, rapid growth was more common in men, in people aged 70 or older, and in patients who had fewer moles and fewer freckles on their skin. The tumors themselves were more often symmetrical, elevated, lighter in color or completely unpigmented, regular in border, and symptomatic, meaning the patient noticed itching, bleeding, or tenderness.4JAMA Dermatology. Rate of Growth in Melanomas: Characteristics and Associations of Rapidly Growing Melanomas
Several of those features are the opposite of what traditional screening advice trains people to look for. The well-known ABCDE checklist (asymmetry, border irregularity, color variation, diameter, evolution) was designed around slowly growing, pigmented melanomas. A fast-growing melanoma in an older man may be symmetrical, evenly colored, and dome-shaped, checking almost none of the classic warning boxes. A separate study confirmed the pattern, finding that a growth rate above 0.4 mm per month was independently associated with older age, male sex, the nodular subtype, ulceration, and a high rate of cell division.5PubMed. Growth rate as a prognostic factor in localized invasive cutaneous melanoma Growth rate itself proved to be an independent prognostic factor for survival, separate from thickness alone.
Genetic Mutations and Growth Speed
The specific genetic mutations driving a melanoma also influence how quickly it grows. BRAF mutations are the most commonly discussed because they are targeted by several approved therapies. But not all BRAF mutations are equal. A study measuring growth rates in millimeters per month found that melanomas carrying the BRAF V600E mutation, the most common BRAF variant, actually tended to grow more slowly than other subtypes, at about 0.12 mm per month. Melanomas with the less common BRAF V600K mutation grew at roughly 0.61 mm per month, and NRAS-mutant melanomas grew at about 0.36 mm per month.6British Journal of Dermatology. The role of BRAF mutations in primary melanoma growth rate and survival
That finding complicates a simple narrative. BRAF V600E is often associated with younger patients and the superficial spreading subtype, yet despite its slower growth, BRAF-mutant early-stage melanoma was still associated with poorer melanoma-specific survival in some analyses. A large study of higher-risk primary melanomas found that both BRAF and NRAS mutations were associated with the presence of mitoses, a marker of active cell division.7JAMA Oncology. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma So the mutations clearly matter, but their relationship to growth speed is not a clean, one-to-one mapping. A slower-growing primary tumor with certain mutations can still carry a worse prognosis than a faster-growing one with a different genetic profile.
Melanomas That Start from Scratch Versus Those That Arise in Moles
Many people assume melanoma always develops from a pre-existing mole that “goes bad,” but the majority of melanomas actually arise de novo, meaning they appear on previously normal-looking skin. This distinction turns out to matter for growth. A cross-sectional study found that melanomas arising within a pre-existing mole had a significantly lower average thickness at diagnosis (about 0.55 mm) compared with de novo melanomas (about 0.84 mm). Mole-associated melanomas also showed much lower mitotic activity, averaging 0.17 cell divisions per square millimeter versus 1.21 for de novo tumors.8PubMed Central. Nevus-Associated and De Novo Melanoma: A Cross-Sectional Study on Prognostic Differences
This pattern held up in a large multi-cohort analysis, which found that de novo melanomas were roughly twice as likely to be thicker than 1.0 mm at diagnosis and more than twice as likely to be the nodular subtype. Patients with de novo melanomas had shorter overall survival across two independent cohorts, and de novo status was an independent predictor of worse outcomes even after adjusting for thickness, ulceration, and other standard prognostic factors.9JNCI: Journal of the National Cancer Institute. De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival Whether de novo melanomas are genuinely faster-growing or simply harder to notice early because there is no changing mole to trigger alarm is still debated, but the clinical result is the same: they tend to be more advanced at the point a doctor sees them.
The Amelanotic Problem
Amelanotic melanomas, those that produce little or no visible pigment, represent one of the trickiest diagnostic challenges in dermatology and have a direct bearing on the growth-speed question. These tumors can appear as pink, red, or flesh-colored bumps or patches, and because they look nothing like the dark, irregular lesions people are trained to watch for, they are frequently misdiagnosed. In one study, melanoma was included in the initial clinical diagnosis for only about a third of red amelanotic melanomas, compared with 94% of pigmented cases.10PubMed Central. Amelanotic Melanomas Presenting as Red Skin Lesions: A Diagnostic Challenge with Potentially Lethal Consequences That diagnostic gap means initial biopsies were more often superficial and incomplete, leaving deep margins positive in 44% of amelanotic cases versus 9% of pigmented melanomas.
But delayed or inadequate diagnosis is not the whole story. Amelanotic melanomas tend to present with thicker Breslow depth, higher mitotic rates, more frequent ulceration, and lower survival than their pigmented counterparts.11Melanoma Research. Amelanotic melanoma A clinical study of 36 amelanotic cases argued that the higher average thickness of these tumors, relative to only a modest increase in diagnostic delay, pointed toward an intrinsically faster speed of growth rather than detection bias alone.12PubMed. Clinical features of 36 cases of amelanotic melanomas and considerations about the relationship between histologic subtypes and diagnostic delay In other words, amelanotic melanomas may genuinely grow more aggressively, not just get caught later. The nodular subtype was particularly common among them.
Lentigo Maligna and the Slow End of the Spectrum
At the opposite extreme from nodular and amelanotic melanomas sits lentigo maligna, a subtype that typically develops on chronically sun-damaged skin, especially the face and neck, in middle-aged and older adults. Lentigo maligna is considered the in situ phase of lentigo maligna melanoma, meaning the abnormal melanocytes remain confined to the outermost layer of skin and have not yet invaded deeper.13PubMed Central. Diagnosis and management of lentigo maligna: a review This in situ phase can persist for years, sometimes well over a decade, as a slowly expanding irregular brown patch.
The slow pace of lentigo maligna can be both reassuring and deceptive. It gives patients and clinicians more time, but it can also breed complacency, especially when the lesion on the cheek or forehead looks stable for years. When lentigo maligna does eventually invade, transforming into lentigo maligna melanoma, it carries the same risk of metastasis as other invasive subtypes of comparable thickness. The BRAF mutation data described earlier fits this picture: lentigo maligna melanoma was less likely to carry a BRAF mutation and, when it did, tended to grow more slowly than the superficial spreading subtype.7JAMA Oncology. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma
Eye Melanoma Grows on a Different Clock
Melanoma does not only arise in the skin. The uveal tract of the eye, particularly the choroid, is the second most common site. Growth kinetics for choroidal melanoma differ substantially from cutaneous melanoma. A systematic review and meta-analysis estimated the average volume doubling time for choroidal melanoma at about 360 days. Small tumors doubled even more slowly, at around 717 days on average, while large tumors doubled in roughly 307 days. For comparison, benign choroidal nevi had an estimated doubling time of over 6,000 days.14PubMed. Choroidal nevi and melanoma doubling times and implications for delays in treatment: A systematic review and meta-analysis The finding that larger tumors double faster suggests a super-exponential growth curve, where growth accelerates as tumor size increases.
Cell type also matters. An earlier study of posterior uveal melanomas found that spindle cell tumors had a mean doubling time of about 292 days, while mixed cell melanomas doubled in roughly 128 days.15PubMed. Growth rates and doubling times of posterior uveal melanomas Once uveal melanoma metastasizes, typically to the liver, the pace changes dramatically. A study of metastatic uveal melanoma found untreated metastases had a median doubling time of 63 days, with a range from 34 to 220 days.16PubMed. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment As with skin melanoma, the jump in speed from primary to metastatic disease is striking.
When Does Melanoma Actually Start Spreading
A question closely related to growth speed is when, in the life of the primary tumor, metastasis actually begins. The traditional assumption was that melanoma first grows locally, then invades deeper layers, and only begins seeding distant sites relatively late, when it is thick enough to reach blood vessels and lymphatics. Emerging evidence suggests the timeline is less orderly. Research using various methodologies has indicated that many melanomas may disseminate tumor cells into the body long before the primary lesion is ever diagnosed.17PubMed Central. When does a melanoma metastasize? Implications for management
This does not mean every thin melanoma has already spread. The immune system plays a critical role in keeping disseminated tumor cells in check. Research in a mouse model of melanoma demonstrated that CD8+ T cells, a key arm of the immune response, are crucial for maintaining dormancy in tumor cells that have already reached distant organs.18JCI Insight. Tumor cells disseminate early, but immunosurveillance limits metastatic outgrowth, in a mouse model of melanoma In this model, tumor cells had scattered early, but the immune system held them in a dormant state, preventing visible metastatic growth. This helps explain a pattern clinicians have seen for decades: late recurrences in melanoma patients who were seemingly cured years or even decades earlier. Dormant cells can reactivate, sometimes triggered by immune suppression from aging, medication, or illness.
Pediatric Melanoma Looks Different
Melanoma in children and adolescents is rare but presents in ways that can make it harder to recognize and, by extension, harder to characterize by typical growth timelines. Pediatric melanoma often does not follow the standard ABCDE screening criteria that work for adults. A review of the topic noted that pediatric melanoma is more frequently amelanotic, may present as a bleeding bump, can be uniform in color, often arises de novo rather than in a pre-existing mole, and can be any diameter.19PubMed Central. Pediatric melanoma: incidence, treatment, and prognosis A modified set of criteria has been proposed for children, adding features like amelanotic appearance and bleeding to the checklist. Because these tumors so often lack the classic melanoma look, the growth that occurs before diagnosis may be particularly hard to track, and delays in recognition remain a significant concern.
The Role of Immunosuppression
One of the strongest external accelerators of melanoma growth is immune suppression. Organ transplant recipients, people with certain blood cancers, and individuals with advanced HIV are all at increased risk of developing melanoma, and when they do, the disease can behave more aggressively. The mechanism is straightforward in concept: a weakened immune surveillance system is less able to detect and destroy abnormal melanocytes early, and less able to restrain disseminated cells that have already left the primary site. This connects directly to the dormancy research mentioned earlier. If CD8+ T cells are the guards holding scattered tumor cells in check, any condition or medication that suppresses those cells loosens the restraints.
For transplant patients on long-term immunosuppressive drugs, the standard advice about watching skin lesions takes on added urgency. Not only are these patients more likely to develop melanoma in the first place, but the tumors they develop may progress more quickly through the stages that normally take months to years. The same logic applies to newer immunotherapies used to treat other conditions: any treatment that dials down the immune response creates a window where existing melanocytic abnormalities might advance faster than they otherwise would.
Mathematical Models and What They Can Predict
Researchers have tried to build mathematical models that predict melanoma growth, partly to improve treatment planning and partly to estimate how long a tumor had been growing before it was found. One approach, the melanoma kinetics index, measures growth in millimeters per month using Breslow thickness (the depth of invasion) as a stand-in for tumor volume. The developers observed a proportional relationship between this growth index and disease-free survival, meaning faster-growing tumors predicted shorter time to recurrence.20Actas Dermo-Sifiliográficas. Tumor Doubling Time in Skin Cancer: Can It Be Estimated and Is It Useful?
More complex computational approaches have emerged, including models that simulate tumor-immune interactions and extracellular matrix remodeling to capture melanoma dynamics over time.21PubMed. Malignant melanoma fractional-order mathematical model with stabilized fuzzy sliding mode control These models are still largely in the research phase and are not yet standard clinical tools, but they reflect a growing recognition that melanoma growth is not a simple exponential curve. It interacts with the immune system, the surrounding tissue, nutrient supply, and genetic drivers in ways that make each tumor’s trajectory somewhat unique. The hope is that better models will eventually let clinicians estimate how long a given melanoma has been present and how urgently it needs to be treated, rather than relying on thickness at diagnosis alone.
Why Screening Remains Unsettled
Given how variable melanoma growth rates are, you might expect a clear consensus on how often people should be screened. There is not one. In the United States, no national consensus exists on skin cancer screening intervals, and the decision about when to recommend total-body skin exams is left largely to individual clinicians.22PubMed Central. Skin cancer screening: recommendations for data-driven screening guidelines and a review of the US Preventive Services Task Force controversy Part of the difficulty is that melanoma’s wide range of growth speeds makes it hard to set a single screening interval that works for everyone. A yearly check might catch a slow-growing superficial spreading melanoma with time to spare but could miss a nodular melanoma that went from invisible to deeply invasive in four months. Conversely, screening every three months for the entire population would be enormously expensive and generate a large number of unnecessary biopsies.
For people at higher risk, including those with a history of melanoma, many moles, fair skin, a family history, or immune suppression, more frequent monitoring and sometimes sequential digital dermoscopy are standard practice. For everyone else, the practical advice remains to know your own skin well enough to notice changes, especially new lesions or existing spots that are growing, changing shape, or developing symptoms like itching or bleeding. The unpredictable pace of melanoma growth means that self-awareness, while imperfect, is probably the most accessible early-warning system available.